HK inno.N recently announced that it has signed a contract to export its finished goods for gastroesophageal reflux disease treatment, "K-Cab," to six countries in North Africa, including Egypt, with the leading local pharmaceutical company in Saudi Arabia, "Tabuk Pharmaceuticals," on the 7th.
Previously, HK inno.N entered into a contract with Tabuk Pharmaceuticals for the export of K-Cab finished goods to 10 countries in the Middle East and North Africa last year. With this additional contract, K-Cab will enter six new North African countries: Egypt, Sudan, Ethiopia, Morocco, Yemen, and Libya.
K-Cab is a domestically produced potassium competitive acid secretion inhibitor (P-CAB). The gastroesophageal reflux disease treatment has evolved from first-generation histamine-2 receptor antagonists (H2RAs) to second-generation proton pump inhibitors (PPIs), and then to third-generation P-CABs. While PPIs are vulnerable to gastric acid and take 4 to 5 days to show effects, P-CAB formulations can be taken regardless of gastric acid levels and show efficacy within one hour.
HK inno.N is expanding its global market presence not only through the export of K-Cab technology but also through finished goods exports. Including this contract, it has achieved a milestone of entering a total of 53 countries overseas, excluding South Korea. Partner company Tabuk Pharmaceuticals is a leading pharmaceutical company with a strong distribution network and marketing capabilities throughout the Middle East and North Africa.
Kwak Dal-won, CEO of HK inno.N, noted, "With this contract, we have surpassed half of our goal of entering 100 countries by 2028," and stated, "We will continue to collaborate closely with our partners in each country to ensure that K-Cab establishes itself as an innovative treatment that transforms the paradigm for gastroesophageal reflux disease overseas."
Ismail Shehada, CEO of Tabuk Pharmaceuticals, stated, "The partnership with HK inno.N is a key pillar of our growth strategy," adding, "We are pleased to strengthen cooperation not only through entry into more countries but also through the future expansion of new product lines."